Medications for Neonatal Onset Multisystem Inflammatory Disease
These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Neonatal Onset Multisystem Inflammatory Disease.
Found 2 Approved Drugs for Neonatal Onset Multisystem Inflammatory Disease
Kineret
Generic Name
Anakinra
Kineret
Generic Name
Anakinra
Form: Injection
Method of administration: Subcutaneous
FDA approval date: December 15, 2009
Classification: Interleukin-1 Receptor Antagonist
KINERET is an interleukin-1 receptor antagonist indicated for: Rheumatoid Arthritis (RA) Reduction in signs and symptoms and slowing the progression of structural damage in moderately to severely active rheumatoid arthritis, in patients 18 years of age or older who have failed 1 or more disease modifying antirheumatic drugs (DMARDs).
Arcalyst
Generic Name
Rilonacept
Arcalyst
Generic Name
Rilonacept
Form: Injection
Method of administration: Subcutaneous
FDA approval date: February 27, 2008
ARCALYST (rilonacept) is an interleukin-1 blocker indicated for: Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS), and Muckle-Wells Syndrome (MWS) in adults and children 12 years and older.
Showing 1-2 of 2
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances